News
Datapharm and Siguru AI Announce Strategic Partnership to Advance MLR Efficiency Across the Pharmaceutical Industry
Mar 18, 2026
Datapharm is excited to announce its strategic partnership with Siguri AI, an innovative technology provider supporting the UK Pharmaceutical Medical review process.
Surrey, UK - 18 March, 2026
Datapharm, the provider of the electronic medicines compendium (emc, medicines.org.uk), today announced its new partnership with Siguru AI, an emerging pioneer in AI (Artificial Intelligence) solutions which support the copy approval process and increase efficiency when ensuring Code compliance for promotional materials.
The collaboration enables Siguru AI to integrate the latest, structured and approved medicine safety information automatically from emc at the moment it is needed. As a result, Pharmaceutical companies can benefit from reducing the risk of outdated information in circulation and enhancing the thoroughness of their AI-driven workflows.
Rob Morgan, CEO of Datapharm, said: "Our mission has always been to ensure that every patient and healthcare professional has access to the most reliable and accessible medicines information. Partnering with Siguru AI allows us to bring the benefit of emc’s structured data into another vital setting, supporting a fantastic innovation made possible with AI, while maintaining the highest standards of accuracy and safety. We’re excited to see how this collaboration improves the success of Pharma’s operational efficiency in a UK Code compliance environment.”
Siguru AI's platform optimises Pharmaceutical companies' medical review process by scanning draft materials in seconds, analysing all Code factors from foundational through to claims, for promotional materials. The AI is used as an assistant for both marketing and medical teams, aiming to reduce MLR (Medical, Legal and Regulatory) cycles from 40 days to 7, and an increase in single rounds of review by 75%.
The partnership reflects a shared commitment to supporting more robust processes for the Pharmaceutical industry's adherence to the ABPI Code of Practice, whilst reducing major bottlenecks for marketing and medical teams.
Dan Bentley, Co-Founder of Siguru AI, spoke of the importance of the partnership: “AI in highly regulated industries must be built on trusted data. Our partnership with Datapharm anchors Siguru in approved SPC information, improving both safety and speed in MLR”.
Leading Code Consultant and Founding Advisory Board Member, Dr. Rina Newton, also commented: “This collaboration signals our intent to work with the most authoritative sources available. Embedding structured SPC data from emc reinforces the credibility of Siguru's reviews and sets a new benchmark for responsible AI in MLR.”
To learn more about Siguru AI, get in touch with its Co-Founder and Director, Harry Bliss:
About Siguru AI
Siguru AI works with pharmaceutical companies to enhance the commercial and medical team's Medical, Legal and Regulatory process. Its AI detection technology has been developed in collaboration with industry-leading pharmaceutical experts to ensure optimal efficiency with rapid adoption since its launch.
Its solution reviews all material types, and acts as a review assistant, helping brand and marketing teams create compliant materials from the start while enabling medical teams to complete essential checks up to 75% faster. By reducing review rounds and strengthening commercial execution, it streamlines approvals and supports high compliance standards.
About Datapharm
Datapharm runs the UK’s trusted medicines information database, emc (electronic medicines compendium), listing more than 10,000 medicines and attracting an audience of millions of visits per year. It is a pharma-preferred partner, providing innovative software solutions to support the Life Sciences and wider Healthcare sectors, serving more than 320 Pharma customers in the UK.
It also partners with a wide range of professional and voluntary health organisations to improve health literacy and decision making about medicines for patients, carers, healthcare professionals and the pharmaceutical industry.